You are here

Antibiotic Combo Shows Promise in Treating Urinary Tract Infections

Ceftolozane/tazobactam superior to levofloxacin in phase III trial (November 25)

Positive results have been reported from a pivotal study of the antibiotic candidate ceftolozane/tazobactam (Cubist Pharmaceuticals) in patients with complicated urinary tract infections (cUTIs). The combination treatment met its primary endpoint of statistical noninferiority compared with levofloxacin (10% noninferiority margin).

The double-blind, randomized, phase III trial compared the safety and efficacy of intravenous (IV) ceftolozane/tazobactam (1.5 g q8h) with that of IV levofloxacin (750 mg qd) in 1,050 adults with cUTI, including those in whom the infection had spread to the kidney (pyelonephritis). The trial’s primary endpoint was a composite of microbiological eradication and the clinical cure rate (composite cure rate) at 5 to 9 days after the end of therapy.

The 95% confidence interval (CI) around the treatment difference had lower and upper bounds of 2.3% and 14.6%, respectively, favoring ceftolozane/tazobactam.

Although this trial was not prospectively designed to demonstrate superiority, the finding that the lower bound of the 95% CI around the positive treatment differences in favor of ceftolozane/tazobactam was greater than zero indicated statistical superiority over levofloxacin.

Ceftolozane/tazobactam, an antibiotic candidate being developed to treat certain Gram-negative infections, consists of ceftolozane, a novel cephalosporin that has demonstrated more potent in vitro activity against Pseudomonas aeruginosa compared with currently available cephalosporins, with tazobactam, a well-established beta-lactamase inhibitor. The addition of tazobactam broadens coverage to include most extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli, Klebsiella pneumoniae, and other Enterobacteriaceae.

Source: Cubist Pharmaceuticals; November 25, 2013.

Recent Headlines

WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs